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Fear strikes at the heart when a diagnosis of
cancer is made. Life as the person knows it is
forever changed. But then consider the added
impact of learning for you or a loved one who has
a rareform of cancer. Perhaps there are only 100
reported cases in the literature – or fewer – and
few researchers, if any, are studying that type of
tumor. This is where our organization, NORD
(www.rarediseases.org) comes into the picture.
When a diagnosis of a rare disorder is made, or
when a diagnosis remains elusive, it is to NORD
that many people turn. 
NORD was established in 1983 after the sign-
ing into law of the Orphan Drug Act by President
Ronald Reagan. This law was the result of the
valiant lobbying efforts by a small group of deter-
mined parents and rare disease group leaders.
Abbey  Meyers,  one  of  those  parents,  is  the
founder of NORD and served as its president for
25  years.  Until  her  retirement  in  2008,  Ms
Meyers was considered the primary consumer
advocate  for  people  with  rare  disorders.  She
spearheaded an organization that has become a
true beacon of hope, providing a way out of the
dark and isolated world of rare diseases. Abbey
Meyers had extraordinary practical and vision-
ary insight. She understood from the start that if
research were to be undertaken for disorders
that affect relatively small populations, it would
need to start at the grass roots level. Thus, short-
ly  after  NORD  became  a  501(c)3  non-profit
organization,  a  medical  advisory  committee
(MAC) was appointed and a clinical research
seed-grant program established. 
NORD’s research grant program attracts out-
standing  researchers  from  within  the  United
States and internationally. Our RFPs are deter-
mined by private donations from individuals and
rare disease patient organizations. The stead-
fast philosophy behind our research grant pro-
gram is that the money is to be used for clinical
research that could not otherwise be undertaken
because of the lack of funding for rare disease
research. The minimum amount awarded for a
RFP is $30,000, but we have received much high-
er funding amounts. We are continually amazed
at  the  funds  that  dedicated  individuals  and
groups  are  able  to  raise  for  rare  disease
research. NORD has received funding for multi-
ple grants in the amount of $50,000 each.
Our MAC, which uses a formal method simi-
lar to that used by NIH for scoring each applica-
tion, determines the researchers who are award-
ed these grants. Examples of the rare cancers for
which NORD has been able to administer clini-
cal seed grants include adenoid cystic carcino-
ma, multiple myleoma, hepatocellular carcino-
ma,  pheochromcytoma,  and  monoclonal  gam-
mopathies. 
It is not an exaggeration to state that people
who have been diagnosed with a rare form of
cancer contact us every week. They are usually
overwhelmed, confused, and feeling desperate.
They may be from rural areas where treatments
for rare diseases are difficult if not impossible to
access, or just as likely may reside in or near
major metropolitan areas. They want to know
where the most current clinical trials are being
conducted, who the experts are, and how to con-
tact them. 
These patients or family members are often
financially devastated. We have literally received
phone calls from people who are supposed to
start radiation therapy the next day, but have
just found out that their insurance will not pay
for it. We recently received a phone call from a
young man in Texas who had just started his
own business and had purchased private med-
ical insurance. Within a month he was diag-
nosed with testicular cancer, and had undergone
an orchiectomy. He was to start radiation thera-
py (RT) within a specific time frame and was
waiting for his insurance to approve the series
of treatments. This individual contacted NORD
because he was supposed to receive his first RT
treatment the following day, but his insurance
company had just advised him that they would
not cover the treatments. The reason they gave
him for denying coverage was that their policy-
holders had to have been in their program for a
minimum  of  six  months  before  “reproductive
treatments” would be covered. He did not have
the finances to pay for even his first radiation
treatment.
We understood immediately that whoever had
denied  his  claim  at  that  insurance  company
obviously misunderstood the need for radiation
treatments.  While  the  treatments  involved  a
reproductive organ, they clearly were not for the
sake of reproduction. We carefully provided him
with the proper wording to explain his situation,
and strongly encouraged him to speak with a
senior level insurance representative. We also
referred him to some excellent patient organiza-
tions  that  are  focused  on  testicular  cancer.
Happily, by the end of that day we learned from
this  young  man,  through  an  e-mail,  that  his
treatments were to be covered and to proceed as
scheduled. In addition to questions about rare
cancers, we hear from people who are struggling
with the effects of the rare group of disorders,
paraneoplastic neurological syndromes (PNS).
We were most fortunate to enlist the help of one
of our country’s foremost researchers on PNS to
help us write a report for patients on this compli-
cated syndrome. He is a member of an interna-
tional consortium of researchers on PNS, and
through our contact with him, we have been able
to  guide  people  to  appropriate  researchers
regardless of the country in which they reside. 
NORD services include:
• Information  in  patient-friendly  language
about rare disorders.
• Referrals to support groups.
• Patient-assistance  programs  to  help  people
obtain certain medications they could not oth-
erwise afford.
• Research grants and fellowships to encourage
the study of rare diseases.
• Advocacy on important public policies.
• Help in locating clinical trials.
• Assistance in identifying resources such as
free air travel for sick children and their par-
ents.
• A monthly news e-blast about the most cur-
rent news on rare disorders.
• A registered nurse (RN) and genetic coun-
selor  to  provide  both  medical  and  genetic
guidance  and  explanations  for  people  who
contact us.
We feel that this is a particularly appropriate
time  to  address  your  readers  because  of  the
upcoming global effort to raise awareness about
rare disorders. The event Rare Disease Day will
be recognized and celebrated both within the
United  States  and  overseas  on  February  28,
2010. The official U.S. Rare Disease Day website
is  http://rarediseaseday.us. Eurordis,  our  sister
organization  in  Europe  (a  group  that  Abbey
Meyers helped form), is the official European
partner  in  this  event.  Their  website  is
http://www.eurordis.org. 
NORD thanks the Rare Tumorsonline medical
journal for providing us with the opportunity to
tell your readership about our organization and
the numerous services that we provide. We hope
that you will feel comfortable about contacting
us, or referring your patients to us for informa-
tion and support. We are entirely dedicated to
our  mission  of  “the  identification,  treatment,
and cure of rare disorders through programs of
education, advocacy, research, and service.”
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